1

1 Title Page

2 Title

- 3 Baseline expression of immune gene modules in blood is associated with primary response
- 4 to anti-TNF therapy in Crohn's disease patients

5 Authors

- 6 Benjamin Y. H. Bai (ORCID: 0000-0003-0765-6398) [1, 2]
- 7 Mark Reppell [3]
- 8 Nizar Smaoui [3]
- 9 Jeffery F. Waring [3]
- 10 Valerie Pivorunas [3]
- 11 Heath Guay [3]
- 12 Simeng Lin [4, 5]
- 13 Neil Chanchlani [4, 5]
- 14 Claire Bewshea [5]
- 15 James R. Goodhand [4, 5]
- 16 UK Inflammatory Bowel Disease Pharmacogenetics Study Group
- 17 Nicholas A. Kennedy [4, 5]
- 18 Tariq Ahmad [4, 5]
- 19 Carl A. Anderson [1]

20 Affiliations

- 21 1. Genomics of Inflammation and Immunity Group, Wellcome Sanger Institute,
- 22 Hinxton, UK;
- 23 2. Postgraduate School of Life Sciences, University of Cambridge, Cambridge, UK;
- 24 3. AbbVie Inc., Chicago, IL, USA;
- 25 4. Department of Gastroenterology, Royal Devon University Healthcare NHS
- 26 Foundation Trust, Exeter, UK;
- 27 5. Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group,
- 28 University of Exeter, Exeter, UK.

29 Short title for running head

30 Baseline module expression associated with anti-TNF response

31 Abbreviations

- 32 ADA: adalimumab
- 33 AIC: Akaike information criterion
- 34 BMI: body mass index
- 35 BTMs: blood transcriptomic modules
- 36 CD: Crohn's disease
- 37 CRP: C-reactive protein
- 38 FDR: false discovery rate
- 39 IBD: inflammatory bowel disease
- 40 IFX: infliximab

3

- 41 IMID: immune-mediated inflammatory disease
- 42 LOR: loss of response
- 43 PANTS: Personalised Anti-TNF Therapy in Crohn's Disease
- 44 PNR: primary non-response/non-responder
- 45 PR: primary response/responder
- 46 TNF: tumour necrosis factor
- 47 UC: ulcerative colitis
- 48 rRNA: ribosomal RNA
- 49 ssGSEA: single-sample gene set enrichment score

50 Address for correspondence

- 51 Carl A. Anderson
- 52 Genomics of Inflammation and Immunity Group, Wellcome Sanger Institute, Hinxton, UK
- 53 CB10 1SA
- 54 Tel: +44 (0)1223 834244
- 55 Fax: +44 (0)1223 494919
- 56 <u>ca3@sanger.ac.uk</u>
- 57

4

58 Abstract

59	Background and Aims. Anti-TNF therapy is widely used for treatment of inflammatory
60	bowel disease (IBD), yet many patients are primary non-responders (PNR), failing to respond
61	to induction therapy. We aimed to identify blood gene expression differences between
62	primary responders (PR) and primary non-responders to anti-TNF monoclonal antibodies
63	(infliximab and adalimumab); and to predict response status from blood gene expression
64	and clinical data.
65	Methods. The Personalised Anti-TNF Therapy in Crohn's Disease (PANTS) study is a UK-wide
66	prospective observational cohort study of anti-TNF therapy outcome in anti-TNF naive
67	Crohn's disease (CD) patients (ClinicalTrials.gov identifier: NCT03088449). Blood gene
68	expression in 324 unique patients was measured by RNA-seq at baseline (week 0), and at
69	weeks 14, 30, and 54 after treatment initiation (total sample size = 814).
70	Results. After adjusting for clinical covariates and estimated blood cell composition,
71	baseline expression of MHC, antigen presentation, myeloid cell enriched receptor, and other
72	innate immune gene modules was significantly higher in anti-TNF responders. Expression
73	changes from baseline to week 14 were generally of consistent direction across patients but
74	with greater magnitude in responders, with the exception of interferon-related genes that
75	were upregulated uniquely in non-responders. Expression differences between responders
76	and non-responders observed at week 14 were maintained at week 30 and week 54.
77	Prediction of response status from baseline clinical data, cell composition, and module
78	expression was poor.

- 79 **Conclusions.** Baseline gene module expression was associated with primary response to
- 80 anti-TNF therapy in PANTS patients. However, these expression differences were insufficient
- 81 for clinically useful prediction of response.

82 Keywords

83 Anti-TNF, transcriptomics, Crohn's disease

85 Introduction

86	Crohn's disease (CD) is a chronic immune-mediated inflammatory disease (IMID) of the
87	gastrointestinal tract. Along with ulcerative colitis (UC), it is one of the two main forms of
88	inflammatory bowel disease (IBD). The development of anti-TNF biologic therapies has
89	revolutionised patient care for CD and a number of other IMIDs over the last two decades.
90	Two major anti-TNF drugs, infliximab and adalimumab, are IgG1 monoclonal antibodies that
91	bind both soluble and transmembrane TNF, inhibiting their interactions with TNF
92	receptors. ^{1,2} Two main mechanisms of action have been proposed: induction of CD4 $^{+}$ T cell
93	apoptosis in the gut mucosa by inhibiting the TNF-TNFR2 interaction; and binding of the
94	antibody tail (Fc region) of the drug to Fc receptors on monocytes, inducing their
95	differentiation into wound-healing M2 macrophages. ^{3,4}
96	
97	Unfortunately, anti-TNF therapy is not always effective at treating IBD. Various types of
98	treatment failure can occur: primary non-response (PNR) within the induction period (the
99	first 12–14 weeks for infliximab and adalimumab), secondary loss of response (LOR) during
100	maintenance therapy after an initial response, failure to achieve remission after the
101	treatment course, or adverse events that lead to treatment discontinuation. ⁵ For IBD
102	patients, the incidence of PNR is 10–40%, and the incidence of secondary LOR among initial
103	responders is 24–46% in the first year of treatment. $^{6-8}$ The ability to predict PNR and LOR
104	could help guide changes in treatment regimens, such as dose intensification or switching to
105	a drug class with a different mechanism of action. ^{2,6} Reliable baseline prediction would be
106	especially valuable, allowing stratification of patients to effective therapies from treatment
107	initiation, minimising healthcare costs and patient burden.

7

108

109	Clinical variables reported to be associated with anti-TNF response include age, disease
110	duration, body mass index (BMI), smoking, C-reactive protein (CRP) levels, faecal
111	calprotectin levels, serum drug concentrations, and anti-drug antibody concentrations.
112	These associations have mostly been reported in small retrospective cohorts and have
113	rarely been independently validated. ^{7,9–13} In the Personalised Anti-TNF Therapy in Crohn's
114	Disease (PANTS) study, the largest study of infliximab and adalimumab response in CD
115	patients to date (enrolment $n = 1610$), baseline obesity, smoking, and greater disease
116	activity were associated with low serum drug concentration after induction. Low drug
117	concentration was in turn associated with PNR and non-remission, suggesting
118	immunogenicity may be mediating treatment failure by increasing drug clearance rate. ⁸
119	
120	Multiple studies have attempted to define transcriptomic predictors for anti-TNF
121	response. ^{12–20} Reported associations include <i>TREM1</i> expression, identified as a marker of
122	anti-TNF response in different studies with inconsistent directions of effect. Gaujoux et al. ¹⁶
123	found TREM1 expression was lower in gut biopsies from infliximab responders than in non-
124	responders (total cohort size $n = 72$), but higher in responders in a separate cohort
125	measuring baseline whole blood expression ($n = 22$). By contrast, Verstockt et al. ¹⁸ reported
126	lower TREM1 expression in responders to infliximab and adalimumab in both baseline gut
127	biopsies ($n = 44$) and baseline whole blood ($n = 54$). Proposed reasons for the discrepancy
128	include false positives due to small sample sizes, differences in patient ethnicity, and
129	differing definitions of response. ^{12,21} In general, small sample sizes, and variation among
130	studies in analysis methods, anti-TNF drug, response definition, tissues sampled, and
131	disease subtype make a consensus hard to establish. Few markers for anti-TNF response of

8

any type, clinical or transcriptomic, have been validated in independent studies, and none
 have yet been translated to routine clinical practice.¹³

- 134
- 135 To identify novel transcriptomic associations with primary response to anti-TNF therapy, we
- 136 generated longitudinal RNA-seq data from peripheral blood samples taken from a subset of
- the PANTS cohort (182 PR, 142 PNR) during the first year of follow-up. Differential gene
- 138 expression (DGE) between primary responders and non-responders was performed at
- 139 baseline (week 0), post-induction (week 14), and during maintenance (week 30 and week
- 140 54). We detected differences in gene module expression that may reflect differences in
- 141 disease characteristics or severity that influence risk of primary non-response. As this is one
- 142 of the largest datasets currently available for assessing transcriptomic associations with
- 143 anti-TNF response in IBD, we also examined the significance of previously reported
- 144 transcriptomic markers from the literature. Finally, we evaluated the utility of measuring
- 145 module expression for prediction of primary response status.

146 Materials and Methods

147 Study design

148	PANTS is a UK-wide, multicentre, prospective observational cohort study reporting the
149	treatment failure rates of the anti-TNF drugs infliximab (originator, Remicade [Merck Sharp
150	& Dohme, Hertfordshire, UK] and biosimilar, CT-P13 [Celltrion, Incheon, South Korea]), and
151	adalimumab (Humira [AbbVie, Cambridge, MA]) in 1610 anti-TNF-naive patients with active
152	luminal CD. The study design has been described in detail previously. ^{8,55} In brief, patients
153	were recruited at the time of first anti-TNF exposure between February 2013 and June 2016,
154	and evaluated for 12 months or until drug withdrawal. Eligible patients were aged \geq 6 years
155	with evidence of active luminal Crohn's disease involving the colon and/or small intestine.
156	Four major study visits were scheduled at first dose (baseline, week 0), post-induction (week
157	14), week 30, and week 54. Additional visits were scheduled at treatment failure or exit. At
158	baseline, clinical and demographic data were recorded, including sex, ethnicity, BMI,
159	smoking status, age at diagnosis, disease duration, Montreal classification, prior medical and
160	drug history, and previous Crohn's disease-related surgeries. At every visit, disease activity
161	score, weight, current therapy, and adverse events were recorded.

162 **RNA-seq sample selection**

163 A subset of PANTS patients was selected for RNA-seq, with the inclusion criteria: age \geq 16 164 years; and baseline CRP \geq 4 mg/L and/or baseline calprotectin > 100 µg/g. The target sample 165 size was 200 patients on infliximab and 200 patients on adalimumab, with an even split

	10
166	between PR and PNR within each drug group. PR and PNR were defined based on Kennedy
167	et al. ⁸ patient outcome criteria:
168	• Primary non-response (assessed at week 14): exit before week 14 because of
169	treatment failure (including resectional inflammatory bowel disease surgery) or
170	corticosteroid use at week 14 (new prescriptions or if previous dose had not been
171	stopped). Patients whose CRP did not decrease to 3 mg/L or less or by 50% or more
172	from baseline (week 0), and whose HBI score did not decrease to 4 points or less or
173	by 3 points or more from baseline, were also classified as having a primary non-
174	response.
175	• Primary response (assessed at week 14): decrease in CRP to 3 mg/L or less or by 50%
176	or more from baseline (week 0) and a decrease in HBI to 4 points or less or by 3
177	points or more from baseline.
178	• Remission (assessed at weeks 14, 30, 54; implies primary response): CRP of 3 mg/L or
179	less and HBI score of 4 points or less, no ongoing steroid therapy, and no exit due to
180	treatment failure.
181	Steroid use was defined as any systemic therapy, either oral or intravenous (including use of
182	steroids for other conditions), but excluding single pre-infusion dosing with hydrocortisone.
183	
184	PNR were required to exhibit primary non-response at week 14 and non-remission at week
185	54. PR were required to exhibit primary response or remission at week 14, and be in
186	remission at week 54 (or week 30 if week 54 status was unknown). Furthermore, within
187	infliximab-treated patients, PNR and non-PNR were matched based on baseline
188	immunomodulator use, baseline steroid use, age at first dose, baseline albumin, sex, and

189 weight at study entry.

190 Whole blood RNA-seq

191	Whole blood was collected in RNA Tempus tubes (Applied Biosystems) and stored at -80°C
192	until extraction (QIAsymphony PAXgene Blood RNA Kit, Qiagen). RNA was quantified using
193	the QuBit BR RNA (ThermoFisher), and RNA integrity was assessed with the 4200
194	TapeStation (Agilent). RNA-seq libraries were prepared using the Kapa mRNA HyperPrep Kit,
195	with depletion of ribosomal RNA (rRNA) and globin mRNA using the QIAseq FastSelect RNA
196	Removal Kit, and adapter ligation with IDT xGEN Dual Index UMI adapters. A total of 1 141
197	samples from 396 patients were sequenced. Raw sequencing data was demultiplexed with
198	Picard ²² and aligned to the reference genome (GRCh38) using STAR (v2.6.1d) ²³ . Reads were
199	deduplicated using UMI-tools ²⁴ and quantified against the Ensembl 96 gene annotation with
200	featureCounts (v1.6.4). ²⁵

201

202 Outlier samples were excluded, defined as > 2 standard deviations from the mean based on 203 percentage of aligned reads in coding regions reported by Picard, percentage of unique 204 reads and number of unique reads. Samples with sex mismatch against documented sex 205 were removed. As gene expression measured from bulk tissue is heavily dependent on cell composition,²⁶ cell proportions of six common cell types in whole blood (CD4⁺ T cells, CD8⁺ T 206 207 cells, B cells, NK cells, monocytes, and granulocytes) were estimated using the Houseman method²⁷ from paired DNA methylation data.²⁸ Samples missing clinical data and/or cell 208 209 proportion estimates were removed. A total of 814 samples remained after filtering. To 210 accommodate variability in sampling day, samples were mapped to timepoints based on 211 Kennedy et al.⁸ windows around major visits: week 0 (week -4-0), week 14 (week 10-20), 212 week 30 (week 22-38), and week 54 (week 42-66). Samples taken at additional visits (LOR

12

213	or exit) falling within one of the windows were mapped to that timepoint, unless the patient
214	also had a major visit sample inside that window. The mapping of samples to timepoints is
215	shown in Fig. S1a. The number of samples per patient ranged from one to four, with a
216	median of three (Fig. S1b).
217	
218	Counts were normalised for library size using edgeR (v3.28.1). ²⁹ Globin genes and short non-
219	coding RNAs were removed, and genes with low expression were filtered, requiring genes to
220	have at least 1.25 counts per million in > 10% of samples and non-zero expression in > 90%
221	of samples. Expression data from 15 511 genes remained after filtering. Finally, log2
222	expression values were generated using variancePartition/voom. ^{30,31}

223 Statistical analyses

224 A full description of the statistical analyses can be found in the Supplementary Methods. In 225 brief, DGE analyses were performed in R (v3.6.2),³² with the significance threshold set at 226 false discovery rate (FDR) < 0.05. Variance components analysis was used to identify 227 influential variables for inclusion in DGE models (Fig. S2). Cell proportion estimates were 228 found to explain large fractions of expression variance, and adjusting for cell proportions 229 reduced the number of significant associations but improved consistency between drug 230 subgroups, with fewer highly significant modules showing significant drug-by-response 231 interaction effects compared to the unadjusted results (Fig. S3). As this study was not 232 designed to compare between drug subgroups, we focused on models adjusted for cell 233 composition, where the improved consistency allows us to pool expression data from both 234 subgroups for greater statistical power. For all DGE models, cell proportions, sequencing 235 batch, age of onset (the patient's age at disease diagnosis), disease duration, body mass

13

index (BMI), anti-TNF drug type, prior surgery, and smoking were included as fixed effects;and patient was included as a random effect.

238

239	Per-gene linear mixed-effects models fit using DREAM (variancePartition v1.16.1) ³³ were
240	used to detect pairwise DGE between study groups. Additionally, natural cubic splines
241	(splines::ns) ³² were fit to explore non-linear expression trajectories over all four timepoints,
242	modelling expression as a function of study day in each group (first drug dose = study day 0).
243	Different expression trajectories were detected by testing for differences in spline
244	parameters between groups. Significant genes from the spline analysis were hierarchically
245	clustered by their mean expression in PR and PNR at each timepoint, and the gap statistic ³⁴
246	was used to define clusters of genes with distinct trajectories. The spline analyses were only
247	performed with drug subgroups pooled, as relatively small sample sizes at week 30 and
248	week 54 precluded stratification by drug.
249	
250	Rank-based gene set enrichment analyses (tmod::tmodCERNOtest, v0.46.2), ³⁵ using blood
251	transcriptomic modules (BTMs) were performed to identify coordinately up or
252	downregulated gene sets. These modules are sets of genes that are coexpressed in whole
253	blood, derived by Li et al. 36 (module names prefixed with "LI") and Chaussabel et al. 37
254	(prefixed "DC") from publicly available expression datasets. Gene set overrepresentation
255	analyses were run for BTMs (tmod::tmodHGtest) and other publicly-available gene sets
256	(gprofiler2∷gost, v0.2.0). ³⁸

257

258 Single-sample gene set enrichment scores (ssGSEA,

259 <u>https://github.com/broadinstitute/ssGSEA2.0/</u>) were computed as a summary measure of

14

260	module expression in a sample, both at baseline and at week 14. Predictive models using
261	clinical variables, cell proportions, and module expression scores (baseline or week 14) to
262	predict response status were constructed using caret (v6.0-86). ³⁹ Multiple predictive
263	algorithms were evaluated: penalised and regularised logistic regression methods, parallel
264	random forest, eXtreme Gradient Boosting, support vector machines with a radial basis, k -
265	nearest neighbours, naive Bayes, and Gaussian process models. Bootstrapping (50
266	replicates) with the AUC metric was used to tune models, evaluate internal performance,
267	and perform model selection. Pairwise tests for the difference in AUCs were performed with
268	pROC. ⁴⁰

269 Ethical statement

- 270 The South West Research Ethics committee approved the study (Research Ethics Committee
- 271 reference: 12/SW/0323) in January 2013. Patients were included after providing informed,
- written consent. The study is registered with ClinicalTrials.gov identifier NCT03088449, and
- the protocol is available at <u>https://www.ibdresearch.co.uk/pants/</u>.

15

275 **Results**

276 Baseline expression modules are associated with post-

277 induction primary non-response

278 After RNA-seg quantification and quality control, expression data was available for 15 511 279 genes and 814 samples. These samples were from 324 patients, whose characteristics are 280 shown in Table 1. No single gene had a significant association between week 0 expression 281 and response in the infliximab subgroup (86 PR, 59 PNR). Expression of NK cell (LI.M7.2) and T cell (LI.M7.1, LI.M7.0) gene modules (BTMs)³⁶ was significantly lower in responders. 282 283 Exclusively in the adalimumab subgroup (66 PR, 57 PNR), PDIA5 (log2 fold change (FC) = -284 0.3512, FDR = 0.006777), KCNN3 (log2 FC = -0.8798, FDR = 0.006777), and IGKV1-9 (log2 FC 285 = -1.223, FDR = 0.04518) had significantly lower expression in responders (Fig. 1a). This was 286 accompanied by lower expression of plasma cell/immunoglobulin (LI.M156.0, LI.M156.1) 287 and cell cycle (LI.M4.0, LI.M4.1) modules (Fig. 1b). This heterogeneity between drug 288 subgroups was robust to model form (Fig. S4) and differences in sample size between 289 subgroups (Fig. S5). A pooled analysis was performed to identify modules consistently 290 differentially expressed in both drug subgroups (152 PR, 116 PNR). MHC-TLR7-TLR8 cluster 291 (LI.M146), antigen presentation (LI.M71, LI.M95.0), and myeloid cell enriched receptor and 292 transporter (LI.M4.3) modules were found to be upregulated at baseline in responders. We 293 also examined previously reported baseline markers in gut mucosal biopsies and blood from the literature, ^{14,15,18,41} and did not find them to be significant in this study (Fig. 1a). 294

16

295 **Expression changes from baseline to post-induction are**

²⁹⁶ largely amplified in primary responders

297 To characterise the changes in gene expression induced by anti-TNF therapy, we compared 298 expression at baseline to expression post-induction, and also estimated the difference 299 between expression changes in responders and non-responders (the timepoint-by-response 300 interaction). As expression changes from week 0 to week 14 were relatively consistent 301 between patients on infliximab and adalimumab after adjusting for cell composition (Fig. 302 S6), we pooled drug subgroups for these models. We found that 5 572 and 626 genes were 303 differentially expressed in responders and non-responders respectively, with 179 genes 304 having a significant timepoint-by-response interaction. Of the genes differentially expressed 305 between week 14 and week 0 in both responders and non-responders, and with a significant 306 timepoint-by-response interaction, nearly all (31/32 genes) had an expression change that 307 was amplified in responders (Fig. 2a). For example, CD177, a neutrophil marker upregulated 308 during inflammation, was downregulated at week 14 in responders to a much greater extent (log2 FC = -2.225, FDR = 4.104×10^{-17}) than in non-responders (log2 FC = -0.8981, FDR 309 310 = 0.004598; interaction FDR = 0.008247). Modules differentially expressed between week 0 311 to week 14 included upregulation of B cell (LI.M47.0), plasma cell (LI.M156.0), and T cell 312 activation (LI.M7.1) modules; and downregulation of immune activation (LI.M37.0), 313 monocyte (LI.M11.0), neutrophil (LI.M37.1), and TLR and inflammatory signalling (LI.M16) 314 modules (Fig. 2b). Amplification of expression changes in responders was also observed at 315 the module level, with nearly all module expression changes aligned in the same direction in 316 responders and non-responders, but with larger effects in responders.

317

17

318	In contrast, GBP2 (a member of a family of guanylate-binding proteins induced by
319	interferons ⁴²) was downregulated from week 0 to week 14 in responders (log2 FC = -0.1783 ,
320	FDR = 0.004878), but upregulated in non-responders (log2 FC = 0.1849, FDR = 0.04502;
321	interaction FDR = 0.005977). At the module level, upregulation of type I interferon response
322	(LI.M127), activated dendritic cell (LI.M165), and antiviral IFN signature (LI.M75) modules
323	was observed in non-responders but not in responders (Fig. 2b). Further gene set
324	enrichment analyses using modules from Chaussabel et al. ³⁷ also revealed annotated
325	interferon gene modules to be significantly upregulated at week 14 in non-responders:
326	DC.M3.4, containing <i>STAT2</i> , <i>GBP5</i> , and <i>PARP14</i> (FDR = 3.447 × 10 ⁻²¹); as well two modules
327	containing <i>IFIT3</i> and <i>GBP2</i> , DC.M1.2 (FDR = 9.492 × 10 ⁻¹⁶) and DC.M5.12 (FDR = 1.355 × 10 ⁻¹⁶)
328	13). None of these modules were differentially expressed from week 0 to week 14 in
329	responders (Fig. 2c), suggesting upregulation of interferon pathways at week 14 occurs

330 uniquely in primary non-responders to anti-TNF.

331 Sustained expression differences between responders and

non-responders during maintenance

As PANTS was an observational study, it was possible to retain patients who continued with anti-TNF therapy even after meeting the study definition of PNR at week 14, enabling us to sample the blood transcriptome at week 30 and week 54 during the maintenance period. Leveraging all 814 samples over the four study timepoints, we tested for general differences in expression trajectory over time, detecting 210 differentially expressed genes between responders and non-responders after adjustment for cell composition. To visualise the expression of these genes and identify common patterns of expression change during anti-

18

340	TNF therapy, significant genes were hierarchically clustered by their expression. Six clusters
341	were identified (Fig. 3a), each with distinct expression trajectories for responders and non-
342	responders (Fig. 3b). Cluster 1 largely comprised genes previously found to have a significant
343	difference in expression change from week 0 to week 14 between responders and non-
344	responders (97/132 genes). The most significant gene was <i>KREMEN1</i> (FDR = 4.287×10^{-4}),
345	part of an inflammatory apoptotic pathway in gut epithelium. ⁴³ Cluster 1 genes were
346	enriched in modules associated with myeloid cells and monocytes (LI.M81, hypergeometric
347	test, FDR = 2.115×10^{-6}), platelet activation (LI.M196, 1.348×10^{-5}), immune activation
348	(LI.M37.0, 1.436 \times 10 ⁻⁴), and TLR and inflammatory signalling (LI.M16, FDR = 2.365 \times 10 ⁻³)
349	(Fig. 3c). Expression trajectories showed cluster 1 genes were more downregulated from
350	baseline in responders than non-responders, likely representing a lower inflammatory state
351	in responders by week 14 that is also maintained at week 30 and week 54. An opposing
352	trend was observed in cluster 5, which contained genes enriched for B cell
353	development/activation (LI.M58, FDR = 0.01653) that were more upregulated from baseline
354	in responders than non-responders.
355	
356	Cluster 3 was uniquely enriched for type I interferon response genes (LI.M127, FDR =
357	0.005681, Fig. 3c). Subsequent enrichment analyses using publicly-available gene sets ³⁸
358	revealed enrichments for type II interferon signalling (WP:WP619, adj. $p = 0.0002826$), and
359	for genes containing putative transcription factor (TF) binding motifs for interferon
360	regulatory factors IRF7 (TF:M00453_1, adj. $p = 0.004768$) and IRF8 (TF:M11684_1, adj. $p =$
361	0.006853; TF:M11685_1, adj. p = 0.01136) (Fig. 3d). The genes in cluster 3 showed opposing
362	directions of expression change from week 0 to week 14 in responders versus non-
363	responders, generating expression differences at week 14 that were sustained at week 30

19

364	and week 54. Of the nine genes in the cluster, eight genes (STAT1, BATF2, GBP1, GBP5, IRF1,
365	TAP1, APOL1, APOL2) had a significant interaction between week 0 to week 14 expression
366	change and response status in the per-gene differential expression analyses. IRF1 and STAT1
367	are key transcription factors for interferon signalling. ^{44,45} Unlike the majority of genes that
368	followed trajectories of greater expression change in responders, genes in interferon
369	response pathways were uniquely upregulated in non-responders.

370 **Prediction of primary non-response from gene expression**

371 and clinical variables

372 Given there were multiple significant module-level associations with primary response 373 status, we evaluated the ability to predict response from module expression, as well as cell 374 proportions and clinical variables. Single-sample gene set enrichment scores (ssGSEA) were 375 computed to summarise module expression per sample. Using baseline module scores, the 376 median resampling AUCs over all combinations of algorithms and predictor sets ranged 377 between 0.5541 and 0.6686 (Fig. S7). The best-performing model was regularised logistic regression (regLogistic; hyperparameters: cost = 0.25, loss = L1, epsilon = 0.01) using clinical 378 379 variables, cell proportions, and module scores as predictors, giving a median resampling 380 AUC of 0.6686, a median sensitivity of 0.5392, and a median specificity of 0.6852, where 381 non-response was the positive class, with a prevalence of 43% (116/268). Including cell 382 proportions and module scores improved predictive performance compared to the model 383 using only clinical variables (bootstrap p = 0.02629), but the increase in AUC was only 2.5% 384 (Fig. 4a). This suggests that clinical variables provided the greatest contributions to baseline

20

385	prediction, especially tho	se variables with hig	h importance in all t	hree models (high

absolute *t*-statistics): smoking history, BMI, and baseline steroid usage (Fig. 4b).

387

388	Performance for predicting primary non-response could be improved by using week 14 cell
389	proportions and module scores (median resampling AUC range 0.6216-0.7957, Fig. S8). The
390	prevalence of non-response at week 14 was 42% (104/246). The best performing predictor
391	was again regularised logistic regression incorporating clinical variables, cell proportions,
392	and module scores as predictors (median resampling AUC = 0.7957, sensitivity = 0.6248,
393	specificity = 0.7961). Here the addition of module scores to the predictor dataset had a
394	larger benefit on predictive performance, with a 6.5% increase in AUC comparing the full
395	model to the model including only clinical variables and cell proportions (bootstrap p =
396	2.306×10^{-10}), with a (Fig. 4c). The week 14 modules with the highest variable importance
397	included TLR and inflammatory signalling (LI.M16), chaperonin mediated protein folding
398	(LI.M204.0, LI.M204.1) and translation initiation factor 3 complex (LI.M245) modules (Fig.
399	4d). Greater predictive performance at week 14 likely reflects the larger clinical and
400	expression differences observed between responders and non-responders after the
401	induction period.

21

403 **Discussion**

404	We found substantial differences in whole blood gene expression between anti-TNF primary
405	responders and non-responders in the PANTS cohort. At baseline, three single-gene
406	associations detected in the adalimumab subgroup implicated similar cell types; IGKV1-9
407	encodes the immunoglobulin light chain variable region that forms part of antibodies
408	produced by plasma cells, <i>KCNN3</i> is annotated to a plasma cell surface signature module
409	from Li et al. ³⁶ (LI.S3), and the expression of both <i>KCNN3</i> and <i>PDIA5</i> is high in plasma cells
410	(www.proteinatlas.org/humanproteome/immune+cell, v21.1) and positively correlated with
411	plasmablast frequencies in blood. ⁴⁶ These genes were downregulated in responders, as was
412	the expression of plasma cell and immunoglobulin modules. In keeping with our
413	observations, Martin et al. ¹⁷ identified plasma cells as part of a correlated module of cell
414	populations, where lower module expression in gut biopsies was associated with better
415	response to anti-TNFs. Baseline plasma cell abundances in gut biopsies have also been
416	reported to be lower in responders, albeit in relatively small cohorts of infliximab patients. ¹⁶
417	Our findings lend credence that associations driven by immune cells observed in gut
418	biopsies may also be observable in blood, a more accessible tissue.
419	
420	Previously reported single-gene baseline markers in gut biopsies and blood were non-
421	significant in this study. For example, TREM1 ^{16,18} was not significantly differentially
422	expressed between responders and non-responders in blood samples from PANTS patients.
423	Our observation is consistent with two recent trials of comparable sample size, SERENE-CD
424	and SERENE-UC, where baseline blood TREM1 expression was not predictive of response in
425	either CD or UC patients. ⁴⁷ A variety of factors could explain failures to replicate reported

22

426	markers from study to study. Many existing studies pool heterogeneous cohorts of patients
427	taking different anti-TNF drugs due to the scarcity of large datasets; even between arms of
428	the PANTS study, we observe within-study differences in expression. Additional between-
429	study variation arises from differences in clinical setting, tissues sampled (e.g. blood versus
430	gut biopsies), and definition of primary response (e.g. endoscopic versus clinical
431	parameters). Any two studies are unlikely to have adjusted for the same combinations of
432	covariates in modelling, including covariates such as cell composition that are influential for
433	bulk expression data. Finally, small sample sizes have considerable sampling error. Despite
434	only finding a small number of single-gene associations in PANTS, we detected multiple
435	novel module-level associations, such as baseline upregulation of MHC-mediated antigen
436	presentation modules in responders. We highly recommend the use of set-based methods
437	that draw on changes in multiple genes, as they are not only better powered, but may be
438	more reproducible compared to single-gene association tests.
439	
440	Leveraging the longitudinal design of PANTS, we characterised the changes in blood gene

441 expression post-induction. Reduced expression of immune activation modules in responders 442 at week 14 is consistent with successful drug inhibition of TNF-mediated inflammation. 443 Decreased inflammation correlates with reduced neutrophil activation and reduced monocyte recruitment,⁴⁸ and apoptosis of monocytes induced by anti-TNF in CD patients 444 has been previously described.⁴³ Certain B cell subsets are reduced in the blood of IBD 445 patients compared to controls,⁴⁹ so upregulation of B cell modules at week 14 may also 446 447 represent a shift towards health. Similar expression changes were observed in responders 448 and non-responders, but with greater magnitude in responders, potentially supporting the hypothesis that response is a continuum. Gaujoux et al.¹⁶ found changes in cell proportions 449

23

450	in response to anti-TNF treatment were amplified in responders; here we demonstrate a
451	similar trend at the transcriptional level in PANTS. Post-induction expression differences
452	between responders and non-responders were sustained at week 30 and week 54 during
453	the anti-TNF maintenance period. Kennedy et al. ⁸ found that "continuing standard dosing
454	regimens after primary non-response was rarely helpful" for inducing remission by week 54.
455	This phenomenon may also be reflected in the blood transcriptome, although non-
456	responders in the PANTS RNA-seq data were selected to exclude patients in remission by
457	week 54, so trajectories for non-responders at week 14 that eventually achieved remission
458	could not be observed. Thus, the observed difference in trajectories between responders
459	and non-responders is likely exaggerated.
460	
461	Unlike the majority of baseline versus post-induction associations, expression changes in
462	genes and modules in the interferon pathway were uniquely upregulated in PANTS non-
463	responders. Previous studies in IBD are conflicting, with Samie et al. ⁵⁰ reporting elevated
464	expression of interferon pathway genes in colonic biopsies from non-responders compared
465	to responders, with no significant change pre-versus post-treatment ($n \approx 40$); and
466	Mavragani et al. ²⁰ reporting a post-treatment reduction in blood interferon expression only
467	in non-responders ($n = 30$). In studies of rheumatoid arthritis (RA), another IMID with
468	licensed anti-TNF therapies, increases in type I interferon-regulated gene expression in
469	blood after infliximab treatment were associated with poor clinical response (discovery $n =$
470	15, validation $n = 18$). ⁵¹ A systematic review of our study with other studies reporting similar
471	associations between interferon pathway genes and anti-TNF response would not only help
472	resolve the direction of effect, if any, but provide an opportunity to consider the shared
473	biology of anti-TNF response in IBD, RA, and other immune-mediated diseases.

24

474

475	An important limitation of our analyses is that PANTS was not designed to compare
476	between drug subgroups. Differences between patients on different anti-TNF drugs can
477	arise from patient and physician preference, influenced by cost, disease severity, location,
478	and comorbidities. Unsurprisingly, many associations with response had significantly
479	different effect sizes in infliximab and adalimumab patient subgroups. We found that
480	adjusting DGE models for estimated proportions of major cell types as a proxy for these
481	uncontrolled factors alleviated heterogeneity between subgroups. However, the adjustment
482	is unlikely to work well for rare cell types, thus the associations we report may reflect
483	differences in cell proportions rather than per-cell expression. Given the myriad of other
484	factors that could drive the remaining heterogeneity, we strongly caution against
485	interpreting associations with different effects in the PANTS infliximab and adalimumab
486	subgroups as drug-driven differences with biological significance, and recommend that
487	future transcriptomic studies consider influential factors such as cell composition.
488	
489	We were unable to build clinically useful predictive models of response incorporating
490	expression data. Using only baseline clinical variables, Kennedy et al. ⁸ used logistic
491	regression with stepwise variable selection based on Akaike information criterion (AIC) to
492	predict response in the full PANTS cohort, achieving AUCs of 0.53 (95% CI 0.46–0.59) for
493	infliximab patients and 0.54 (0.46–0.62) for adalimumab patients. Whilst our best-
494	performing baseline model represents an improvement, expression data only contributed a
495	small amount of predictive power on top of clinical variables and cell composition.
496	Unsurprisingly, models had greater predictive power when provided with week 14
497	expression and cell composition data, and adding expression data also provided a

25

498	comparatively large increase in AUC. This suggests that when expression differences
499	between responders and non-responders are sufficiently large, transcriptomic markers do
500	provide unique information, and are not simply proxies for clinical variables or coarse
501	estimates of blood cell composition. A potential route to more effective prediction is to
502	consider whether expression differences arising early in the induction period can
503	discriminate between responders and non-responders. For example, Mesko et al. ⁵² found
504	that week 2 blood gene expression was predictive of infliximab response in CD (discovery n
505	= 20, validation $n = 20$) and RA (discovery $n = 19$, validation $n = 15$) patients. More recently,
506	Mishra et al. ⁵³ trained random forest models using blood DNA methylation and gene
507	expression measured in IBD patients receiving infliximab ($n = 37$). They did not find
508	consistent baseline-only predictive signatures, but a model combining baseline with week 2
509	measurements predicted response in the Mesko et al. cohort with 85% accuracy (95% CI:
510	62–97%). As we observed in PANTS, expression differences between responders and non-
511	responders were far greater by week 14 than at baseline. Post-induction associations were
512	also more consistent between drug subgroups, as baseline differences are diluted by the
513	large transcriptomic perturbation from taking an anti-TNF. Expression changes in the innate
514	immune system are observable within hours of treatment initiation, ⁵³ and robust prediction
515	of non-response within that timeframe may be more valuable than a less reliable prediction
516	at baseline.
517	

In conclusion, we observed significant differences in gene module expression between
responders and non-responders to anti-TNF therapy in the whole blood of PANTS CD
patients at baseline and post-treatment timepoints. Interferon-induced genes were
uniquely upregulated post-induction in non-responders, going against the general trend of

26

- 522 amplified transcriptomic change in responders versus non-responders. However, there is
- 523 not yet a consensus on the direction of these effects, and we were unable to robustly
- 524 predict response with our current sample size. To obtain accurate prediction, especially
- 525 from baseline data, leveraging large upcoming datasets with paired drug response
- 526 phenotypes and transcriptomic data such as the 1000IBD project will be essential.⁵⁴

528 Funding

529	PANTS is an investigator-led	study funded b	y CORE (renamed	Guts UK in 2018),	the research
-----	------------------------------	----------------	-----------------	-------------------	--------------

- 530 charity of the British Society of Gastroenterology, and by unrestricted educational grants
- 531 from AbbVie Inc, USA, Merck Sharp & Dohme Ltd, UK, NAPP Pharmaceuticals Ltd, UK, Pfizer
- 532 Ltd, USA, Celltrion Healthcare, South Korea, and Cure Crohn's Colitis (Scottish IBD Charity).
- 533 The sponsor of the PANTS study is the Royal Devon and Exeter National Health Service
- 534 Foundation Trust. Data generation, sequencing, and sample analysis were funded by
- 535 AbbVie. This research was funded in whole, or in part, by the Wellcome Trust [grant
- 536 numbers 206194, 108413/A/15/D, and 222850/Z/21/Z]. For the purpose of Open Access,
- 537 the author has applied a CC BY public copyright licence to any Author Accepted Manuscript
- 538 version arising from this submission.

539 Conflicts of Interest

540 Mark Reppell, Nizar Smaoui, Jeffery F. Waring, Valerie Pivorunas, and Heath Guay are 541 employees of AbbVie and may own stock and/or options. Simeng Lin reports non-financial 542 support from Pfizer outside the submitted work. James R. Goodhand reports grants from F. 543 Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants 544 from Galapagos NV and non-financial support from Immundiagnostik outside the conduct of 545 the study. Nicholas A. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from 546 Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial 547 support from Immundiagnostik; grants and non-financial support from AbbVie, grants and

28

548	personal fees from Celltrion, personal fees and non-financial support from Janssen, personal
549	fees from Takeda, and personal fees and non-financial support from Dr Falk, outside the
550	submitted work. Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La
551	Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos
552	NV and non-financial support from Immundiagnostik; personal fees from Biogen inc, grants
553	and personal fees from Celltrion Healthcare, personal fees and non-financial support from
554	Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees
555	from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer,
556	personal fees from Genentech and non-financial support from Tillotts, outside the
557	submitted work. Carl A. Anderson has received consultancy or lectureship fees from
558	Genomics plc, BridgeBio, and GSK. The remaining authors have no conflicts of interest to
559	report.

560 Author Contributions

561	SL, NC, JRG, NAK, TA, and CAA participated in the conception and design of the study. CB
562	was the project manager and coordinated recruitment. BYHB, MR, NS, JFW, VP, HG, SL, NC,
563	CB, JRG, NAK, TA, and CAA were involved in the acquisition, analysis, or interpretation of
564	data. The data analysis was performed by BYHB, MR, SL, and NAK. Drafting of the
565	manuscript was conducted by BYHB. All authors contributed to the revision of the
566	manuscript for critically important intellectual content. TA obtained the funding for the
567	study. CAA is the guarantor of the manuscript. All authors contributed to the final approval
568	of the manuscript.

29

Acknowledgements

570	We would like to acknowledge Jim Butler, Areej Ammar, Erin Murphy, Stephen Abel,
571	Elizabeth Asque, and Justin Wade Davis from AbbVie Inc., Chicago, IL, USA for supporting
572	this work. Laboratory tests were undertaken by the Exeter Blood Sciences Laboratory at the
573	Royal Devon & Exeter (RD&E) NHS Trust (https://www.exeterlaboratory.com/). The Exeter
574	NIHR Clinical Research Facility coordinated sample storage and management. The sponsor
575	of the study was the Royal Devon and Exeter NHS Foundation Trust. Simeng Lin is supported
576	by a🛛Wellcome🖾GW4-CAT fellowship (222850/Z/21/Z). Neil Chanchlani acknowledges
577	support from Crohn's & Colitis UK. We thank the patients who participated in the PANTS
578	study, the Inflammatory Bowel Disease Pharmacogenetic Study Group, and research nurses
579	who collected clinical data and biological samples at each study visit. We acknowledge the
580	study co-ordinators of the Exeter IBD Research Group, United Kingdom: Marian Parkinson
581	and Helen Gardner-Thorpe for their ongoing administrative support to the study.

582 Data Availability

Individual participant de-identified data that underlie the results reported in this article will
be available immediately after publication for a period of 5 years. The data will be made
available to investigators whose proposed use of the data has been approved by an
independent review committee. Analyses will be restricted to the aims in the approved
proposal. Proposals should be directed to Tariq Ahmad (tariq.ahmad1@nhs.net) and Carl A.

30

588 Anderson (ca3@sanger.ac.uk). To gain access data requestors will need to sign a data access

589 agreement.

591 **References**

- 1. Adegbola, S.O., Sahnan, K., Warusavitarne, J., Hart, A., and Tozer, P. (2018). Anti-TNF
- 593 Therapy in Crohn's Disease. Int. J. Mol. Sci. *19*, 2244. 10.3390/ijms19082244.
- 594 2. Lichtenstein, G.R. (2013). Comprehensive review: antitumor necrosis factor agents in
- 595 inflammatory bowel disease and factors implicated in treatment response. Ther. Adv.
- 596 Gastroenterol. *6*, 269–293. 10.1177/1756283X13479826.
- 597 3. Neurath, M.F. (2014). New targets for mucosal healing and therapy in inflammatory
- 598 bowel diseases. Mucosal Immunol. 7, 6–19. 10.1038/mi.2013.73.
- 4. Levin, A.D., Wildenberg, M.E., and van den Brink, G.R. (2016). Mechanism of Action of
- Anti-TNF Therapy in Inflammatory Bowel Disease. J. Crohns Colitis *10*, 989–997.
- 601 10.1093/ecco-jcc/jjw053.
- 5. Roda, G., Jharap, B., Neeraj, N., and Colombel, J.-F. (2016). Loss of Response to Anti-TNFs:
- Definition, Epidemiology, and Management: Clin. Transl. Gastroenterol. 7, e135.
- 604 10.1038/ctg.2015.63.
- 605 6. Ben-Horin, S., Kopylov, U., and Chowers, Y. (2014). Optimizing anti-TNF treatments in
- inflammatory bowel disease. Autoimmun. Rev. 13, 24–30. 10.1016/j.autrev.2013.06.002.
- 607 7. Flamant, M., and Roblin, X. (2018). Inflammatory bowel disease: towards a personalized
- 608 medicine. Ther. Adv. Gastroenterol. *11*, 1756283X1774502. 10.1177/1756283X17745029.
- 609 8. Kennedy, N.A., Heap, G.A., Green, H.D., Hamilton, B., Bewshea, C., Walker, G.J., Thomas,
- A., Nice, R., Perry, M.H., Bouri, S., et al. (2019). Predictors of anti-TNF treatment failure in

32

611	anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre,	
-----	--	--

- 612 cohort study. Lancet Gastroenterol. Hepatol. *4*, 341–353. 10.1016/S2468-1253(19)30012-
- 613 3.
- 614 9. D'Haens, G.R., Panaccione, R., Higgins, P.D.R., Vermeire, S., Gassull, M., Chowers, Y.,
- Hanauer, S.B., Herfarth, H., Hommes, D.W., Kamm, M., et al. (2011). The London Position
- 616 Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With
- 617 the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug
- to Choose, and How to Predict Response?: Am. J. Gastroenterol. *106*, 199–212.
- 619 10.1038/ajg.2010.392.
- 620 10. Ding, N.S., Hart, A., and De Cruz, P. (2016). Systematic review: predicting and optimising
- 621 response to anti-TNF therapy in Crohn's disease algorithm for practical management.
- 622 Aliment. Pharmacol. Ther. *43*, 30–51. 10.1111/apt.13445.
- 623 11. Kopylov, U., and Seidman, E. (2016). Predicting durable response or resistance to
- antitumor necrosis factor therapy in inflammatory bowel disease. Ther. Adv.
- 625 Gastroenterol. *9*, 513–526. 10.1177/1756283X16638833.
- 626 12. Digby-Bell, J.L., Atreya, R., Monteleone, G., and Powell, N. (2019). Interrogating host
- 627 immunity to predict treatment response in inflammatory bowel disease. Nat. Rev.
- 628 Gastroenterol. Hepatol. 10.1038/s41575-019-0228-5.
- 13. Noor, N.M., Verstockt, B., Parkes, M., and Lee, J.C. (2020). Personalised medicine in
- 630 Crohn's disease. Lancet Gastroenterol. Hepatol. 5, 80–92. 10.1016/S2468-

631 1253(19)30340-1.

632	14. Ariis, I., Li, K.	. Toedter. G.	. Quintens. R.	. Van Lommel, L.,	Van Steen. K	., Leemans, P., De
	=	,	,,,,	,		.,

- Hertogh, G., Lemaire, K., Ferrante, M., et al. (2009). Mucosal gene signatures to predict
- response to infliximab in patients with ulcerative colitis. Gut *58*, 1612–1619.
- 635 10.1136/gut.2009.178665.
- 636 15. Arijs, I., Quintens, R., Van Lommel, L., Van Steen, K., De Hertogh, G., Lemaire, K.,
- 637 Schraenen, A., Perrier, C., Van Assche, G., Vermeire, S., et al. (2010). Predictive value of
- 638 epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm.
- 639 Bowel Dis. *16*, 2090–2098. 10.1002/ibd.21301.
- 640 16. Gaujoux, R., Starosvetsky, E., Maimon, N., Vallania, F., Bar-Yoseph, H., Pressman, S.,
- 641 Weisshof, R., Goren, I., Rabinowitz, K., Waterman, M., et al. (2019). Cell-centred meta-
- analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of
- 643 patients with IBD. Gut 68, 604–614. 10.1136/gutjnl-2017-315494.
- 644 17. Martin, J.C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J.A., Gettler, K., Chuang,
- 645 L., Nayar, S., Greenstein, A.J., et al. (2019). Single-Cell Analysis of Crohn's Disease Lesions
- 646 Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.
- 647 Cell *178*, 1493-1508.e20. 10.1016/j.cell.2019.08.008.
- 18. Verstockt, B., Verstockt, S., Dehairs, J., Ballet, V., Blevi, H., Wollants, W.-J., Breynaert, C.,
- 649 Van Assche, G., Vermeire, S., and Ferrante, M. (2019). Low TREM1 expression in whole
- 650 blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine 40, 733-
- 651 742. 10.1016/j.ebiom.2019.01.027.
- 19. West, N.R., Hegazy, A.N., Owens, B.M.J., Bullers, S.J., Linggi, B., Buonocore, S., Coccia,
- 653 M., Görtz, D., This, S., Stockenhuber, K., et al. (2017). Oncostatin M drives intestinal

654	inflammation and predicts response to tumor necrosis factor-neutralizing therapy in
655	patients with inflammatory bowel disease. Nat. Med. <i>23</i> , 579–589. 10.1038/nm.4307.
656	20. Mavragani, C.P., Nezos, A., Dovrolis, N., Andreou, NP., Legaki, E., Sechi, L.A., Bamias,
657	G., and Gazouli, M. (2020). Type I and II Interferon Signatures Can Predict the Response
658	to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the
659	Microbiota. Inflamm. Bowel Dis. <i>26,</i> 1543–1553. 10.1093/ibd/izaa216.
660	21. Verstockt, B., Verstockt, S., Blevi, H., Cleynen, I., de Bruyn, M., Van Assche, G., Vermeire,
661	S., and Ferrante, M. (2019). TREM-1, the ideal predictive biomarker for endoscopic
662	healing in anti-TNF-treated Crohn's disease patients? Gut 68, 1531–1533. 10.1136/gutjnl-
663	2018-316845.
664	22. Broad Institute (2019). Picard toolkit. https://broadinstitute.github.io/picard/.
665	23. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson,
666	M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics
667	<i>29</i> , 15–21. 10.1093/bioinformatics/bts635.
668	24. Smith, T., Heger, A., and Sudbery, I. (2017). UMI-tools: modeling sequencing errors in
669	Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 27, 491–
670	499.10.1101/gr.209601.116.
-	

- 671 25. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose
- 672 program for assigning sequence reads to genomic features. Bioinforma. Oxf. Engl. 30,
- 673 923–930. 10.1093/bioinformatics/btt656.

674 26. Piasecka, B., Duffy, D., Urrutia	, A., Quach, H., Pa	atin, E., Posseme,	C., Bergstedt, J.,
--	---------------------	--------------------	--------------------

- 675 Charbit, B., Rouilly, V., MacPherson, C.R., et al. (2018). Distinctive roles of age, sex, and
- 676 genetics in shaping transcriptional variation of human immune responses to microbial
- 677 challenges. Proc. Natl. Acad. Sci. *115*, E488–E497. 10.1073/pnas.1714765115.
- 678 27. Houseman, E.A., Accomando, W.P., Koestler, D.C., Christensen, B.C., Marsit, C.J., Nelson,
- 679 H.H., Wiencke, J.K., and Kelsey, K.T. (2012). DNA methylation arrays as surrogate
- 680 measures of cell mixture distribution. BMC Bioinformatics 13, 86. 10.1186/1471-2105-13-
- 681 86.
- 682 28. Lin, S., Hannon, E., Reppell, M., Waring, J. F., Smaoui, N., Pivorunas, V., Guay, H.,
- 683 Chanchlani, N., Bewshea, C., Bai, B. Y. H., Kennedy, N. A., Goodhand, J. R., Mill, J., Ahmad,
- 584 T., & PANTS Consortium. (2023). Whole blood DNA methylation changes are associated
- 685 with anti-TNF drug concentration in patients with Crohn's disease. MedRxiv.
- 686 https://doi.org/10.1101/2023.03.22.23287574
- 687 29. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package
- 688 for differential expression analysis of digital gene expression data. Bioinformatics 26,
- 689 139–140. 10.1093/bioinformatics/btp616.
- 690 30. Hoffman, G.E., and Schadt, E.E. (2016). variancePartition: interpreting drivers of
- 691 variation in complex gene expression studies. BMC Bioinformatics 17. 10.1186/s12859-
- 692 016-1323-z.
- 693 31. Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: precision weights unlock
- 694 linear model analysis tools for RNA-seq read counts. Genome Biol. 15, 1–17.

- 695 32. R Core Team (2019). R: A language and environment for statistical computing.
- 696 33. Hoffman, G.E., and Roussos, P. (2020). dream: Powerful differential expression analysis
- 697 for repeated measures designs. Bioinformatics. 10.1093/bioinformatics/btaa687.
- 698 34. Tibshirani, R., Walther, G., and Hastie, T. (2001). Estimating the number of clusters in a
- data set via the gap statistic. J. R. Stat. Soc. Ser. B Stat. Methodol. *63*, 411–423.
- 700 10.1111/1467-9868.00293.
- 35. Weiner 3rd, J., and Domaszewska, T. (2016). tmod: an R package for general and
- 702 multivariate enrichment analysis. 10.7287/peerj.preprints.2420v1.
- 36. Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt,
- D.S., Johnson, S.E., Milton, A., Rajam, G., et al. (2013). Molecular signatures of antibody
- responses derived from a systems biology study of five human vaccines. Nat. Immunol.
- 706 *15*, 195–204. 10.1038/ni.2789.
- 37. Chaussabel, D., Quinn, C., Shen, J., Patel, P., Glaser, C., Baldwin, N., Stichweh, D.,
- Blankenship, D., Li, L., Munagala, I., et al. (2008). A Modular Analysis Framework for
- Blood Genomics Studies: Application to Systemic Lupus Erythematosus. Immunity 29,
- 710 150–164. 10.1016/j.immuni.2008.05.012.
- 711 38. Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., and Vilo, J. (2019).
- g:Profiler: a web server for functional enrichment analysis and conversions of gene lists
- 713 (2019 update). Nucleic Acids Res. 47, W191–W198. 10.1093/nar/gkz369.
- 714 39. Kuhn, M. (2020). caret: Classification and regression training.

37

715	40. Robin, X.,	Turck, N., Hainard	l, A., Tik	berti, N., Lisace	ek, F., Sanc	hez, JC., and	Müller, M.
-----	----------------	--------------------	------------	-------------------	--------------	---------------	------------

- 716 (2011). pROC: an open-source package for R and S+ to analyze and compare ROC curves.
- 717 BMC Bioinformatics *12*, 77. 10.1186/1471-2105-12-77.
- 718 41. Salvador-Martín, S., Raposo-Gutiérrez, I., Navas-López, V.M., Gallego-Fernández, C.,
- 719 Moreno-Álvarez, A., Solar-Boga, A., Muñoz-Codoceo, R., Magallares, L., Martínez-Ojinaga,
- 720 E., Fobelo, M.J., et al. (2020). Gene Signatures of Early Response to Anti-TNF Drugs in
- 721 Pediatric Inflammatory Bowel Disease. Int. J. Mol. Sci. 21, 3364. 10.3390/ijms21093364.
- 42. Tretina, K., Park, E.-S., Maminska, A., and MacMicking, J.D. (2019). Interferon-induced
- guanylate-binding proteins: Guardians of host defense in health and disease. J. Exp. Med.
- 724 *216*, 482–500. 10.1084/jem.20182031.
- 43. Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., and Kucharzik, T.
- 726 (2001). Infliximab induces apoptosis in monocytes from patients with chronic active
- 727 Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121, 1145-
- 728 1157. 10.1053/gast.2001.28702.
- 44. Liu, S.-Y., Sanchez, D.J., Aliyari, R., Lu, S., and Cheng, G. (2012). Systematic identification

730 of type I and type II interferon-induced antiviral factors. Proc. Natl. Acad. Sci. *109*, 4239–

731 4244. 10.1073/pnas.1114981109.

- 45. Schneider, W.M., Chevillotte, M.D., and Rice, C.M. (2014). Interferon-Stimulated Genes:
- A Complex Web of Host Defenses. Annu. Rev. Immunol. 32, 513–545. 10.1146/annurev-
- 734 immunol-032713-120231.

735	46. Tsang, J.S., Schwartzberg, P.L., Kotliarov, Y., Biancotto, A., Xie, Z., Germain, R.N., Wang,
736	E., Olnes, M.J., Narayanan, M., Golding, H., et al. (2014). Global Analyses of Human
737	Immune Variation Reveal Baseline Predictors of Postvaccination Responses. Cell 157,
738	499–513. 10.1016/j.cell.2014.03.031.
739	47. Verstockt, B., Pivorunas, V., Al Mahi, N., Smaoui, N., Guay, H., Kennedy, N.A., Ahmad, T.,
740	Goodhand, J.R., Lin, S., Bai, B.Y.H., et al. (2022). Baseline Whole Blood Gene Expression of
741	TREM-1 Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative
742	Colitis or Crohn's Disease in the SERENE Studies. Manuscr. Prep.
743	48. Prame Kumar, K., Nicholls, A.J., and Wong, C.H.Y. (2018). Partners in crime: neutrophils
744	and monocytes/macrophages in inflammation and disease. Cell Tissue Res. 371, 551–565.
745	10.1007/s00441-017-2753-2.

- 746 49. Pararasa, C., Zhang, N., Tull, T.J., Chong, M.H.A., Siu, J.H.Y., Guesdon, W., Chavele, K.M.,
- 747 Sanderson, J.D., Langmead, L., Kok, K., et al. (2019). Reduced CD27-IgD- B Cells in Blood
- and Raised CD27-IgD- B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel
- 749 Disease. Front. Immunol. 10. 10.3389/fimmu.2019.00361.
- 750 50. Samie, M., Lim, J., Verschueren, E., Baughman, J.M., Peng, I., Wong, A., Kwon, Y.,
- 751 Senbabaoglu, Y., Hackney, J.A., Keir, M., et al. (2018). Selective autophagy of the adaptor
- TRIF regulates innate inflammatory signaling. Nat. Immunol. *19*, 246–254.
- 753 10.1038/s41590-017-0042-6.
- 754 51. van Baarsen, L.G., Wijbrandts, C.A., Rustenburg, F., Cantaert, T., van der Pouw Kraan,
- 755 T.C., Baeten, D.L., Dijkmans, B.A., Tak, P.P., and Verweij, C.L. (2010). Regulation of IFN

39

756	response gene activi	y during infliximab	treatment in rheumatoid arthritis is associated
-----	----------------------	---------------------	---

- with clinical response to treatment. Arthritis Res. Ther. *12*, R11. 10.1186/ar2912.
- 758 52. Mesko, B., Poliska, S., Váncsa, A., Szekanecz, Z., Palatka, K., Hollo, Z., Horvath, A.,
- 759 Steiner, L., Zahuczky, G., Podani, J., et al. (2013). Peripheral blood derived gene panels
- 760 predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med.
- 761 *5*, 59. 10.1186/gm463.
- 762 53. Mishra, N., Aden, K., Blase, J.I., Baran, N., Bordoni, D., Tran, F., Conrad, C., Avalos, D.,
- 763 Jaeckel, C., Scherer, M., et al. (2022). Longitudinal multi-omics analysis identifies early
- blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
- 765 Genome Med. 14, 110. 10.1186/s13073-022-01112-z.
- 766 54. Imhann, F., Van der Velde, K.J., Barbieri, R., Alberts, R., Voskuil, M.D., Vich Vila, A., Collij,
- 767 V., Spekhorst, L.M., Van der Sloot, K.W.J., Peters, V., et al. (2019). The 1000IBD project:
- 768 multi-omics data of 1000 inflammatory bowel disease patients; data release 1. BMC
- 769 Gastroenterol. 19. 10.1186/s12876-018-0917-5.
- 55. Sazonovs, A., Kennedy, N.A., Moutsianas, L., Heap, G.A., Rice, D.L., Reppell, M.,
- 771 Bewshea, C.M., Chanchlani, N., Walker, G.J., Perry, M.H., et al. (2019). HLA-DQA1*05
- 772 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and
- Adalimumab in Patients With Crohn's Disease. Gastroenterology.
- 774 10.1053/j.gastro.2019.09.041.

40

776 Figure Captions

777	Figure	1. Baseline expression associated with primary response, adjusted for cell
778	compo	osition.
779	a.	Volcano plots of DGE between responders (PR) and non-responders (PNR) at week 0;
780		for infliximab (IFX), adalimumab (ADA), or with drug subgroups pooled. Annotated
781		genes show significant associations from this study, and previously reported
782		associations from the literature in both blood and gut biopsies. Dashed line shows
783		significance threshold at FDR = 0.05.
784	b.	Top gene modules differentially expressed between PR and PNR at week 0. Columns
785		correspond to results for infliximab (IFX), adalimumab (ADA), difference between IFX
786		and ADA (IFX – ADA i.e. drug-by-response interaction), and pooled drug analyses.
787		The top 30 modules ranked by minimum FDR in any column are shown. Dashed lines
788		show significance thresholds at FDR = 0.05.
789		
790	Figure	2. Expression changes from baseline to post-induction are amplified in responders.
791	a.	Expression log2 fold changes from week 0 to week 14 in primary responders (PR) and
792		non-responders (PNR), for genes that differentially expressed from week 0 to week
793		14 in both responders and non-responders, with a significantly different effect size
794		between responders and non-responders (top 10 labelled). The identity line is shown
795		by the dashed line.
796	b.	Top modules differentially expressed between week 14 and week 0, adjusted for cell
797		composition. Columns show effects in primary responders (PR), non-responders
798		(PNR), and the primary responder minus non-responder difference. The top 30

41

799		modules ranked by minimum FDR in any column are shown. Vertical dashed line
800		shows significance threshold at FDR = 0.05.
801	C.	Barcode plots showing interferon modules (LI/DC) specifically upregulated from
802		week 0 to week 14 in primary non-responders (PNR), but not in primary responders
803		(PR). Genes were ranked in ascending order by week 14 versus week 0 DGE z-
804		statistic. Curves show the cumulative fraction of genes in each module. Effect sizes
805		are represented by the area under the curves (AUCs). Diagonal line shows the null of
806		randomly-distributed ranks.
807		
808	Figure	3. Sustained expression differences between responders and non-responders
809	during	maintenance.
810	a.	Gap statistic versus cluster number <i>k</i> from hierarchical clustering of genes with
811		significant expression differences between PR and PNR over all timepoints. Error
812		bars derived from 500 bootstraps. The optimal cluster number was selected to be $k =$
813		6 by the factoextra::fviz_nbclust firstSEmax criteria
814		(https://rpkgs.datanovia.com/factoextra/index.html).
815	b.	Normalised expression over study timepoints for genes in each cluster. 95%
816		confidence intervals for expression are shown for each group at each timepoint.
817	c.	Gene modules enriched in each cluster from gene set overrepresentation analyses
818		using tmod::tmodHGtest. Modules significantly enriched in any cluster are shown.
819		Vertical dashed line shows significance threshold at FDR = 0.05.
820	d.	Gene sets enriched in cluster 3 from gene set overrepresentation analyses using
821		gprofiler2::gost. Vertical dashed line shows significance threshold at adjusted p-

822 value = 0.05 (gost g:SCS multiple testing correction method).

42

023

824 Figure 4. Prediction of response status from clinical variables, cell proportions, and

825 expression data.

- 826 ROC curves for the regLogistic method trained on each predictor dataset are shown at
- baseline (a) and week 14 (c). ROC curves were plotted after merging all 50 resamples.
- 828 Primary non-response was used as the positive class. DeLong 95% confidence intervals for
- the AUC are shown.
- 830 The ten most important variables from models trained on each predictor dataset are shown
- for baseline (b) and week 14 (d) models. The overall variable importance score is computed
- from the absolute value of the *t*-statistic for each predictor from the final tuned models.
- 833 Missing bars denote variable that were not in the predictor dataset for that model.

834 **Tables**

Table 1. Baseline patient characteristics for the PANTS RNA-seq subcohort.

- 836 Characteristics are stratified by drug subgroup. Values shown are count and percentage for
- 837 categorical variables, and mean and standard deviation for continuous variables. Nominal *p*-
- values are reported for the comparison between drug subgroups.

	adalimumab (ADA)	infliximab (IFX)	drugs pooled	<i>p</i> -value
Sex				0.317 Eisher evact
	70 (40 40/)	00 (54 60/)		FISHER EXACT
FEIVIALE	78 (48.4%)	89 (54.6%)	167 (51.5%)	
MALE Age of encot (years)	83 (51.6%)	74 (45.4%)	157 (48.5%)	0.774
Age of onset (years)		22.0 (15.2)		
Missing	33.3 (15.4)	32.8 (15.3)	33.1 (15.3)	wilcoxon rank-sum
Nissing	U	U	U	0 546
Moon (SD)	C 1 (9 1)	E Q (7 7)	60 (79)	Wilcovon rank sum
Missing	0.1 (0.1)	5.5(7.7)	0.0 (7.9)	
Wissing	U	U	0	0.262
				U.263
(COI 76) Current	28 (17.4%)	36 (22.1%)	64 (19.8%)	FISHER EXACL
Ex	55 (34.2%)	43 (26.4%)	98 (30.2%)	
Never	78 (48 4%)	84 (51 5%)	162 (50.2%)	
Crobp's-related surgery	/0 (1011)0)	01 (021070)	102 (001070)	0.549
(Col %)				Fisher evact
NO	114 (70.8%)	110 (67.5%)	224 (69.1%)	Tisher exact
YES	47 (29.2%)	53 (32.5%)	100 (30.9%)	
On immunomodulator ever	(/	(,		0.5/13
				Fisher exact
NO	23 (14.3%)	28 (17.2%)	51 (15.7%)	Tisher exact
YES	138 (85.7%)	135 (82.8%)	273 (84.3%)	
On immunomodulator at baseline (Col %)		. ,		0.912 Fisher exact
NO	79 (49 1%)	81 (49 7%)	160 (49 4%)	
VES	82 (50 9%)	82 (50 2%)	164 (50.6%)	
On corticosteroids at baseline	62 (50.5%)	02 (50.570)	104 (50.070)	0.011 Eisher exact
NO	112 (70.2%)	92 (56 1%)	205 (63 2%)	institet exact
VES	113 (70.270)	52 (50.470) 71 (42.6%)	110 (26 7%)	
Baseline BMI	48 (23.870)	71 (45.070)	115 (50.770)	0 237
Mean (SD)	25.2 (6.2)	24 3 (5 5)	24.8 (5.9)	Wilcoxon rank-sum
Missing	0	2 110 (010)	0	
Primary response status (Col %)				0.263 Fisher exact
Primary non-response	76 (47,2%)	66 (40.5%)	142 (43.8%)	
Primary response	85 (52.8%)	97 (59.5%)	182 (56.2%)	
CD8 ⁺ T cell (%)				0.380
Mean (SD)	2.8 (4.2)	2.8 (5.2)	2.8 (4.7)	Wilcoxon rank-sum
Missing	38	18	56	
CD4 ⁺ T cell (%s)				0.752
Mean (SD)	9.2 (6.3)	9.2 (6.8)	9.2 (6.5)	Wilcoxon rank-sum
Missing	38	18	56	
B cell (%s)				0.094
Mean (SD)	1.9 (2.0)	1.5 (1.9)	1.7 (1.9)	Wilcoxon rank-sum
Missing	38	18	56	
Monocyte (%s)				0.497
Mean (SD)	8.9 (3.5)	9.2 (3.7)	9.0 (3.6)	Wilcoxon rank-sum
Missing	38	18	56	
NK cell (%s)				0.683
Mean (SD)	1.9 (3.2)	1.9 (3.8)	1.9 (3.5)	Wilcoxon rank-sum
Missing	38	18	56	
Granulocyte (%s)	7/2/07	7/ 2 /10 01	7/ 3 (10 2)	0.911 Wilcoxon rank sum
Missing	74.5 (9.7)	74.5 (10.8)	74.5 (10.5)	www.coxonnank-Sum
iviissing	38	18	56	





-0.5

log2(FC)

1.0 -1.0 -0.5



Not significant

10

b

0.0 - IGKV1-9 -1.0 -0.5

0.5 1.0









С



PNR



(ranked)





b